share_log

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

Insmed在《科學》2024年度生物製藥最佳僱主榜單上排名第一
PR Newswire ·  10/25 04:05

—Insmed Leads Science Top Employers List for Fourth Year in a Row—

Insmed連續四年蟬聯科學頂級僱主榜首

BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.

2024年10月24日,美國新澤西州布里奇沃特/美通社 – 納斯達克上市公司Insmed Incorporated(納斯達克股票代碼:INSM)是一家以人爲本的全球生物製藥公司,致力於提供首選和最佳療法,改變面臨嚴重疾病患者的生活。今天宣佈,該公司在《科學》雜誌的2024年度頂級僱主調查中榮獲最高排名。該年度調查對生物技術、製藥及相關行業的員工進行調查,以確定20家最佳僱主及其核心特質。

"It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year," said Will Lewis, Chair and Chief Executive Officer of Insmed. "This past year has been transformational for our company, as we've demonstrated the strength of our commercial and pipeline programs, continued to fuel the innovation engine behind our early-stage research, and enhanced our culture while growing to more than 1,200 employees around the world. Looking to the future, I am filled with pride and excitement as I think about the talent, dedication, and potential of our team as we strive to make a real difference in the lives of patients with serious diseases."

Insmed董事兼首席執行官Will Lewis表示:「連續第四年被評爲《科學》雜誌年度調查中的第一名,對我們而言是一項巨大榮譽。過去一年對我們公司來說是變革性的,我們展示了商業和管道計劃的實力,繼續推動我們早期研究創新引擎,並在全球範圍內擴展了我們的團隊規模至1200多名員工,同時增強了我們的文化。展望未來,想到我們的團隊的才能、奉獻精神和潛力,讓我充滿自豪和期待,因爲我們致力於在嚴重疾病患者的生活中真正產生影響。」

The 2024 survey results were based on nearly 6,500 responses from individuals located primarily across North America (65%), Europe (19%), and Asia/Pacific Rim (11%). This year's highest-ranking companies stood out in the areas of innovative leadership, respect for employees, social responsibility, employee loyalty, and personal and professional value alignment.

2024年調查結果基於近6500份來自主要位於北美(65%)、歐洲(19%)和亞太地區(11%)的個人回應。今年排名最高的公司在創新領導力、對員工的尊重、社會責任、員工忠誠度以及個人和專業價值觀一致性方面脫穎而出。

"The culture we've built at Insmed is unlike any other I've experienced, and I am proud to see it continue to grow and strengthen as we expand our global team," said Nicole Schaeffer, Chief People Strategy Officer of Insmed. "Thank you to our colleagues around the world who show up every day with a desire to help patients, enrich our communities, and support one another. It is because of you that we have once again been recognized by Science as the top employer in the biopharma industry."

Insmed首席人才戰略官Nicole Schaeffer表示:「我們在Insmed建立的企業文化與我經歷過的任何其他文化都不同,我爲看到它不斷增長和加強,隨着我們擴大全球團隊而感到自豁。感謝我們全球各地的同事,每天都懷着幫助患者、豐富社區和相互支持的願望而過。正是因爲你們,我們再次被《科學》雜誌認定爲生物製藥行業的頂級僱主。」

The complete feature and company rankings can be accessed here. To learn more about Insmed's culture and explore opportunities to join our team, please visit .

完整功能和公司排名可在此處訪問。要了解更多關於insmed文化的信息,並探索加入我們團隊的機會,請訪問。

About Insmed

關於Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

insmed公司是一家以人爲本的全球生物製藥公司,致力於提供一流和最佳療法,改變患有嚴重疾病的患者的生活。該公司正在推進一系列已獲批和中後期研究的藥物以及聚焦於爲需求最大的患者群體提供服務的尖端藥物發現。insmed最先進的項目涉及肺部和炎症疾病,包括在美國、歐洲和日本獲批用於治療慢性、令人衰弱的肺部疾病的一種治療方法。該公司的早期研究項目涵蓋各種技術和模式,包括基因療法、AI驅動的蛋白工程、蛋白質製造、RNA端連接和合成拯救。

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit to learn more.

總部位於新澤西州布里奇沃特,insmed在美國、歐洲和日本各地設有辦公室和研究場所。insmed自豪地成爲生物製藥行業最佳僱主之一,包括連續四年獲得科學頂級僱主第一的榮譽。訪問,以了解更多。

Contact:

聯繫方式:

Investors:

投資者:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
[email protected]

Bryan Dunn
執行董事,投資者關係
Insmed
(646) 812-4030
[email protected]

Media:

媒體:

Mandy Fahey
Vice President, Corporate Communications
Insmed
(732) 718-3621
[email protected]

Mandy Fahey
企業通信副總裁
Insmed
(732) 718-3621
[email protected]

SOURCE Insmed Incorporated

Insmed Incorporated

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?

440k+
440k+

Newsrooms &
新聞發佈室&

Influencers
影響力人士
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
新聞記者

Opted In
Opted In
GET STARTED
開始使用

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論